10-Q: Adial Pharmaceuticals Reports Q1 2025 Results, Highlights AD04 Development and Recent Financing

Sentiment:

Quarterly Report 14 May 2025 4:02 PM

📋All filings for Adial Pharmaceuticals, INC

Adial Pharmaceuticals reports a net loss for Q1 2025, focusing on AD04 development and securing additional funding through a warrant inducement agreement.

Capital raiseThe company states that its current cash and cash equivalents are not expected to be sufficient to fund operations for the twelve months from the date of filing this Quarterly Report on Form 10-Q.The company will require additional financing as it continues to execute its overall business strategy, including two additional Phase 3 trials for AD04 that are currently expected to require $8-12 million each in direct expenses, and up to $5 million in additional other development expenses.The company is actively pursuing financing and other strategic plans but can provide no assurances that such financing or other strategic plans will be available on acceptable terms, or at all.

Worse than expectedThe company reported a net loss of $2.2 million for Q1 2025.The company's auditor has expressed doubt about its ability to continue as a going concern.The company's stockholders equity of $2.1 million is below the Nasdaq minimum requirement of $2.5 million.The company received a notice from Nasdaq that it did not maintain the Minimum Bid Price Requirement as required by Nasdaq Listing Rule 5550(a)(2).

Summary

Adial Pharmaceuticals reported a net loss of $2.2 million for the three months ended March 31, 2025, compared to a net loss of $6.5 million for the same period in 2024.
Research and development expenses increased to $747,000 from $454,000 year-over-year, driven by CMC expenses and consulting fees.
General and administrative expenses rose slightly to $1.52 million from $1.39 million year-over-year.
The company recognized a $150,000 milestone payment from Adovate, LLC.
Adial's cash and cash equivalents stood at $2.4 million as of March 31, 2025, and increased to $3.9 million by May 12, 2025, following a warrant inducement agreement.
The company anticipates its current funds will be sufficient to fund operations into the fourth quarter of 2025.
Adial is actively pursuing additional financing options to support its AD04 clinical development program.
The company's independent auditor has expressed doubt about its ability to continue as a going concern.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the ongoing losses, the going concern warning from the auditor, and the need for additional financing. However, there are some positive developments, such as the FDA feedback and patent issuance, which temper the negative outlook.

Positives

The net loss decreased from $6.5 million in Q1 2024 to $2.2 million in Q1 2025.
The company received a $150,000 milestone payment from Adovate, LLC.
Adial secured $2.35 million in net proceeds through a warrant inducement agreement.
The FDA provided positive feedback on the in-vitro bridging strategy for AD04.
Key patents were issued in the United States and Europe for AD04's precision medicine approach.
The FDA reaffirmed the acceptance of heavy-drinking-day based endpoints as a basis for approval for the treatment of Alcohol Use Disorder.

Negatives

Adial Pharmaceuticals reported a net loss of $2.2 million for Q1 2025.
The company's auditor has expressed doubt about its ability to continue as a going concern.
The company needs additional financing to continue operations and develop AD04.
The company's stockholders equity of $2.1 million is below the Nasdaq minimum requirement of $2.5 million.
The company received a notice from Nasdaq that it did not maintain the Minimum Bid Price Requirement as required by Nasdaq Listing Rule 5550(a)(2).

Risks

Adial faces risks related to raising additional capital to fund operations and AD04 development.
Failure to meet Nasdaq's continued listing requirements could result in delisting of the company's stock.
Future sales of common stock could result in dilution of existing stockholders' ownership.
The company's independent auditor has expressed doubt about its ability to continue as a going concern.
The company's current cash and cash equivalents are not expected to be sufficient to fund operations for the twelve months from the date of filing this Quarterly Report on Form 10-Q.

Future Outlook

Adial expects to continue focusing on the clinical development of AD04, particularly in specific genetic subgroups, and plans to initiate a Phase 3 clinical trial in the second half of 2025. The company anticipates needing additional funding to support these activities and sustain operations.

Management Comments

The company is preparing for the next FDA interaction to confirm the Phase 3 clinical plan in the United States.
Management is actively pursuing financing and other strategic plans but can provide no assurances that such financing or other strategic plans will be available on acceptable terms, or at all.

Industry Context

Adial's focus on precision medicine for addiction treatment aligns with a growing trend in the pharmaceutical industry towards personalized therapies. The FDA's acceptance of heavy-drinking-day based endpoints and the 2-level reduction of the World Health Organization (WHO) risk drinking levels of alcohol consumption as an efficacy endpoint in pivotal clinical trials with adults diagnosed with (AUD) reflects a shift towards more practical and patient-centric outcome measures in AUD clinical trials.

Comparison to Industry Standards

Adial's cash position of $2.4 million as of March 31, 2025, is relatively low compared to other clinical-stage biopharmaceutical companies.
For example, companies like Biohaven Pharmaceutical Holding Company (now part of Pfizer) and Alkermes have historically maintained significantly larger cash reserves to fund their extensive clinical trial programs.
Adial's Q1 2025 R&D expenses of $747,000 are also modest compared to companies in similar stages of development.
Companies like Sage Therapeutics, which focuses on central nervous system disorders, typically spend several million dollars per quarter on R&D.
Adial's reliance on warrant exercises and equity purchase agreements for funding is a common strategy for smaller biotech companies, but it can lead to significant dilution for existing shareholders.
Larger pharmaceutical companies often have access to more diverse funding sources, including debt financing and partnerships with other companies.

Stakeholder Impact

Shareholders face potential dilution from future equity offerings.
Employees' job security is dependent on the company securing additional funding.
The success of AD04 could benefit patients with alcohol use disorder.
The company's creditors face increased risk due to the going concern warning.

Next Steps

Continue clinical development of AD04, focusing on specific genetic subgroups.
Prepare for the next FDA interaction to confirm the Phase 3 clinical plan in the United States.
Initiate a Phase 3 clinical trial of AD04 in the second half of 2025.
Pursue additional financing options to support operations and AD04 development.
Actively monitor the bid price of the common stock and consider available options to regain compliance with the Nasdaq listing requirements.

Key Dates

Date	Description
November 23, 2010	Adial Pharmaceuticals, LLC formed in Virginia.
October 5, 2017	Adial converted to a corporation and reincorporated in Delaware.
July 31, 2018	2017 Equity Incentive Plan became effective.
March 24, 2019	Company entered into a consulting agreement with Dr. Bankole A. Johnson.
January 26, 2021	Purnovate, Inc. was formed as a wholly owned subsidiary.
September 8, 2022	Dr. Johnsons Consulting Agreement was amended to increase his annual compensation.
August 31, 2022	Received notice from Nasdaq regarding Minimum Bid Price Requirement.
March 15, 2023	Company entered into a Master Services Agreement with the Keswick Group, LLC.
May 31, 2023	Existing Equity Purchase Agreement entered into with Alumni Capital, LLC.
June 30, 2023	Adovate issued to the Company a 19.9% equity stake in Adovate.
August 4, 2023	Reverse stock split effected to regain compliance with Nasdaq listing requirements.
August 21, 2023	Received notice from the Staff notifying us that the Staff has determined that for 10 consecutive business days, from August 7, 2023 to August 18, 2023, the closing bid price of our common stock has been at $1.00 per share or greater.
January 17, 2024	Company entered into a statement of work #2 (SOW #2) with the director and Keswick Group, pursuant to which the director was appointed as Chief Operating Officer of Adial.
March 1, 2024	Warrants to purchase 268,440 shares of common stock at an exercise price of $2.82 per share were exercised for gross proceeds of approximately $757 thousand.
March 1, 2024	Company entered into the Inducement Agreement pursuant to which the Holder of the Existing Warrants exercised for cash the Existing Warrants to purchase up to approximately 1,150,000 shares of common stock, at an exercise price of $2.82 per share.
April 10, 2024	Company provided Dr. Johnson with notice of the termination of the Companys consulting agreement with him.
April 24, 2024	Company and Dr. Johnson executed a separation agreement.
May 17, 2024	Dr. Johnson ceased serving as the Companys Chief Medical Officer.
August 20, 2024	Payment of $40,000 was made to Dr. Johnson.
August 18, 2024	Company issued 2,400 shares of common stock to Dr. Johnson on achievement of certain milestones.
December 13, 2024	Existing Equity Purchase Agreement with Alumni Capital, LLC was cancelled and a new Equity Purchase Agreement was entered into.
January 27, 2025	Company issued 100,000 shares of common stock to a vendor and cash of $4,970 in consideration for services rendered valued at $100,000.
February 4, 2025	Received positive response from the FDA on its proposed in-vitro bridging strategy for AD04.
March 5, 2025	Received written notice from Nasdaq notifying us that for the preceding 30 consecutive business days (January 17, 2025 through March 4, 2025), our common stock did not maintain the Minimum Bid Price Requirement as required by Nasdaq Listing Rule 5550(a)(2).
April 1, 2025	Consulting agreement with Keswick MSA was terminated.
April 15, 2025	Patent number 12,274,692 was issued by the United States Patent and Trademark Office.
May 2, 2025	Company entered into a warrant inducement agreement with an existing healthcare-focused institutional investor.
May 5, 2025	Warrant inducement transaction closed.
May 13, 2025	66,667 additional shares of common stock had been sold subsequent to the quarter ended March 31, 2025 under the terms of the New SEPA for a total of $42,396 leaving a remaining $4.9 million to be sold under the New SEPA.
September 1, 2025	Compliance period ends to regain compliance with Nasdaq Listing Rule 5550(a)(2).
March 31, 2028	Company is required to use commercially reasonable efforts to achieve the goals of submitting a New Drug Application to the FDA for a licensed product.
March 31, 2029	Company is required to use commercially reasonable efforts to achieve the goals of commencing commercialization of an FDA approved product.

Keywords

AD04, Alcohol Use Disorder, Clinical Trials, Pharmaceuticals, Financing, Warrants, FDA, Patents, Liquidity, Going Concern

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.